Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

04 Apr 2025 15:21 CEST

Oslo, Norway, 4 April, 2025 - Reference is made to the stock exchange notice
published by Zelluna ASA (the "Company") on 27 March 2025 regarding key
information on the reverse share split at a ratio of 10:1.

Radforsk Investeringsstiftelse ("Radforsk") has previously agreed with the
Company to make available, without any compensation a, necessary number of
shares to ensure that all fractions of shares are rounded up to the nearest
whole share, thus avoiding that shareholders will have its shareholdings rounded
off downwards.

Radforsk has today transferred a total of 1730 shares to DNB Bank ASA,
registrar's department, for deletion, to ensure that all fractions of shares are
rounded up to the nearest whole share in the reverse share split.

The Company has thus received the following notification of a transaction made
by a close associate of a primary insider:

* Radforsk Investeringsstiftelse, a close associate of Anders Tuv, Chair of
the board of directors and primary insider of the Company, has today
transferred 1730 existing shares in the Company to DNB Bank ASA, registrar's
department, at a price of NOK 1 per share (equal to the par value).

The notification concerning the above subscription is attached hereto.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

More information:
Access the news on Oslo Bors NewsWeb site

643069_20250404 - Zelluna ASA - PDMR attachment.pdf